Understanding Access to Weight-Loss Injections

Three years back, a friend of mine, a fashion editor, came back from Milan Fashion Week with quite a tale. Most of her colleagues stayed in the same hotel, and each room boasted a mini fridge. On their way to the airport, a stylist suddenly recalled an “important package” left behind in his fridge and called the hotel, frantic not to have it discarded. Turns out, he had forgotten his Ozempic.

Back then, Ozempic wasn’t really a household term. Yet, behind the scenes, this injectable medication for type 2 diabetes was being discreetly used off-label for weight loss. Fast forward to today: the scenario has shifted significantly. “So many fashion insiders are on it now, and they’re quite open about it,” she tells me.

Famous figures like Serena Williams, Elon Musk, and Whoopi Goldberg have openly discussed their use of weight-loss injections, and medications like Wegovy and Mounjaro are now even available through the NHS, generating quite a buzz in the media.

You’d think this would level the playing field, enabling people grappling with obesity to access help without paying hefty private fees. But, that’s not quite the case.

It’s estimated that numerous NHS patients are missing out. With the NHS limiting access, some professionals worry that a two-tier system of weight-loss drugs is forming, benefiting those who can afford them. Martin Fidock from Ovivia, which provides Wegovy and support to NHS patients, mentions that discrepancies in eligibility criteria across regions create a “postcode lottery.” Evidence suggests around 1.5 million individuals in the UK use these drugs; however, over 90% are thought to pay privately. Depending on the dosage and included support, this can cost anywhere from £100 to £350 monthly.

Recently, pharmaceutical giant Eli Lilly was rumored to increase the list price of Mounjaro by as much as 170%. They later negotiated a deal for UK distributors, which may lessen potential price hikes, but concerns still linger. Brad, a tech worker in his 40s, worries about affordability after losing 20kg but facing rising drug costs.

Nutritionists and GPs express concerns that the growing disparity in access to weight-loss drugs could exacerbate existing health inequalities. Katharine Jenner from the Obesity Health Alliance argues, “We can’t let health become a luxury for the rich.” Is it possible that these injections, despite their advantages, are turning obesity into a matter of wealth?

The NHS ‘postcode lottery’

While weight-loss drugs have been on the NHS for some time, the introduction of newer options like semaglutide (Wegovy) and tirzepatide (Mounjaro) changed the game. Wegovy got NHS approval for obesity treatment in 2023, while Mounjaro followed suit earlier this year. These medications work by suppressing appetite through hormone mimicry, with studies suggesting users can lose up to 20% of their body weight.

They are available for people with a BMI of 27 or higher (with a health condition) or above 30 otherwise, adjusting for certain ethnicities. However, tougher conditions have emerged, and in England and Wales, access is largely restricted to those with a BMI over 35.

Local health boards have considerable say in how weight-loss medications are administered, and Martin Fidock asserts that some areas have raised the BMI threshold, potentially limiting access further. Novo Nordisk, the company making Wegovy, shares concern over increasing access disparities, indicating that many must pay out-of-pocket, which is unfeasible in deprived areas where obesity rates are notably high.

NHS England suggests that differences in access may reflect varying levels of need or activity among providers but leaves budget decisions to local regions.

For Mounjaro, NHS England has started prescribing it to people with a BMI above 40 who have specific health conditions. Though the rollout began in June, a report indicates not all practices have started offering it. Just 18 out of 42 NHS boards have confirmed they’re prescribing it as planned. This disparity raises questions about equitable access to essential treatments.

Many from deprived backgrounds face a greater struggle with obesity, and more than a third are categorized as obese—double the figure in wealthier neighborhoods. This brings the serious risk of social and health implications, including higher instances of cancer and heart disease. Moreover, a study found that the earning potential of obese individuals can be lower, further complicating the issue.

In the meantime, a private market for these weight-loss injections has surged. Sara de Souza from Nottingham is among those benefiting from it. After gaining weight post-pregnancy that she couldn’t shed through dieting, she sought a prescription but was ineligible for NHS support. Paying £200 a month through a weight-loss app, she eventually lost all the weight she’d gained.

Sara describes the transformation as life-changing and insists she’d pay the price again for the significant benefits. However, not everyone shares her experience or means. A recent poll reveals that while 18% of overweight individuals might pay for weight-loss drugs, a staggering 59% would prefer NHS access.

Meanwhile, individuals concerned about private cost increasing may find the situation troubling. Pete Beech, who battled obesity and paid £160 a month for Mounjaro, calls attention to the consequences of NHS rationing beyond mere weight challenges.

Issues also arise concerning a weight-loss drug black market, as not all services ensure thorough screening before prescribing. Health experts stress the importance of proper medical assessments, noting potential risks associated with side effects and the need for proper prescriptions.

‘Not a magic bullet’

The discussion around expanding NHS access continues, albeit within the bounds of cost considerations. Analysts suggest competition among emerging weight-loss drugs could eventually help drive down prices. There are currently over 160 weight-loss drugs in clinical development, hinting at potential improvements in accessibility.

Earlier this year, a think tank recommended that NHS should offer these medications to individuals with BMIs over 27, positing that addressing obesity’s societal costs—estimated at £98 billion annually—would ultimately benefit the economy. They proposed a means-tested approach to ensure equitable access while considering economic impact.

Nonetheless, NHS England maintains that while they are reviewing all options, these weight-loss drugs are not a “magic bullet.” This consideration leads to a broader discourse on whether medical solutions might risk overshadowing the more pressing social issues that perpetuate obesity.

Focusing solely on medical remedies may divert attention from necessary discussions surrounding food industry regulations—the true origins of obesity issues. The complexities are deep-rooted, and addressing them requires more than a quick fix.

In the grand scheme, navigating these intertwined challenges—of public health, personal responsibility, and economic disparity—remains an ongoing quest. Society’s approach varies, but clearly, the conversation is far from over.